In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Subcommittee To Deliberate GPO Legislation At Sept. 8 Hearing

This article was originally published in The Gray Sheet

Executive Summary

Annual HHS certification of GPO compliance with federal anti-competition regulations would be authorized under a proposal being floated by the Senate Judiciary/Antitrust Subcommittee

You may also be interested in...



GPO Self-Regulation Flaws Dictate Legislation – Former FTC Attorney Balto

Testimony by David Balto, a former FTC policy director, that more regulation is needed to penalize GPOs in violation of their "codes of conduct" could convince Sens. Mike DeWine (R-Ohio) and Herb Kohl (D-Wisc.) that legislation is required

GPO Self-Regulation Flaws Dictate Legislation – Former FTC Attorney Balto

Testimony by David Balto, a former FTC policy director, that more regulation is needed to penalize GPOs in violation of their "codes of conduct" could convince Sens. Mike DeWine (R-Ohio) and Herb Kohl (D-Wisc.) that legislation is required

GPO hearing rescheduled

Senate Judiciary Committee/Antitrust, Competition Policy & Consumer Rights Subcommittee will host Sept. 14 hearing on "Hospital Group Purchasing: How to Maintain Innovation and Cost Savings." A discussion draft that would authorize annual HHS certification of GPO compliance with federal anti-competition regulations likely will be circulated at the hearing, previously scheduled for Sept. 8 (1"The Gray Sheet" Sept. 6, 2004, p. 25)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020851

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel